Subretinal fluid morphology in chronic central serous chorioretinopathy and its relationship to treatment: a retrospective analysis on PLACE trial data.
Central Serous Chorioretinopathy
/ diagnosis
Chronic Disease
Female
Fluorescein Angiography
/ methods
Follow-Up Studies
Fundus Oculi
Humans
Male
Middle Aged
Photochemotherapy
/ methods
Photosensitizing Agents
/ therapeutic use
Retrospective Studies
Subretinal Fluid
/ diagnostic imaging
Tomography, Optical Coherence
/ methods
Treatment Outcome
Verteporfin
/ therapeutic use
Visual Acuity
central serous chorioretinopathy
imaging
optical coherence tomography
subretinal fluid
volume analysis
Journal
Acta ophthalmologica
ISSN: 1755-3768
Titre abrégé: Acta Ophthalmol
Pays: England
ID NLM: 101468102
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
07
03
2021
accepted:
18
04
2021
pubmed:
18
5
2021
medline:
27
1
2022
entrez:
17
5
2021
Statut:
ppublish
Résumé
To explore subretinal fluid (SRF) morphology in chronic central serous chorioretinopathy (cCSC) after one session of either high-density subthreshold micropulse laser (HSML) treatment or half-dose photodynamic therapy (PDT). We retrospectively obtained optical coherence tomography (OCT) scans from a subset of patients from a randomized controlled trial on treatment-naïve eyes with cCSC allocated to either HSML treatment or half-dose PDT. OCT scans were evaluated prior to treatment and 6-8 weeks post-treatment, where we measured maximum SRF height and width, calculated the maximum height-to-maximum width-ratio (maxHWR) and calculated the total SRF volume. Forty-one eyes of 39 cCSC patients were included. SRF morphology ranged from flat to dome-shaped, quantified as maxHWR ranging between 0.02 and 0.12. SRF volume was median 0.373 μl (range: 0.010-4.425 μl) and did not correlate to maxHWR (rho = -0.004, p = 0.982). Half-dose PDT was superior to HSML treatment in complete SRF resolution (RR = 3.28, p = 0.003) and in morphological changes of SRF (Δ SRF morphology changed after both HSML treatment and half-dose PDT in cCSC, with SRF disappearing in most PDT-treated patients, whereas SRF volume increased in a sizeable proportion of HSML-treated patients. Baseline SRF characteristics measured in this study were unable to predict outcomes after either HSML treatment or half-dose PDT.
Identifiants
pubmed: 33998168
doi: 10.1111/aos.14901
pmc: PMC9292654
doi:
Substances chimiques
Photosensitizing Agents
0
Verteporfin
0X9PA28K43
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
89-95Subventions
Organisme : Stichting Blinden-Penning
Organisme : Stichting tot Verbetering van het Lot der Blinden
Organisme : Stichting Leids Oogheelkundig Ondersteuningsfonds
Organisme : Algemene Nederlandse Vereniging ter voorkoming van Blindheid
Organisme : Rotterdamse Stichting Blindenbelangen
Organisme : Stichting Ooglijders
Organisme : Stichting Blindenhulp
Organisme : Retina Nederland Onderzoek Fonds
Organisme : Landelijke Stichting voor Blinden en Slechtzienden
Organisme : the Netherlands Organisation for Scientific Research
Organisme : Mathilde Grant
Organisme : Macula Fonds
Informations de copyright
© 2021 The Authors. Acta Ophthalmologica published by John Wiley & Sons Ltd on behalf of Acta Ophthalmologica Scandinavica Foundation.
Références
Mol Genet Genomic Med. 2019 Apr;7(4):e00576
pubmed: 30724488
Prog Retin Eye Res. 2015 Sep;48:82-118
pubmed: 26026923
Lancet. 2020 Jan 25;395(10220):294-303
pubmed: 31982075
Graefes Arch Clin Exp Ophthalmol. 2019 Jul;257(7):1419-1425
pubmed: 31123815
Am J Ophthalmol. 2020 Apr;212:187-188
pubmed: 32007226
Eye (Lond). 2019 Jan;33(1):14-33
pubmed: 29995841
Ophthalmology. 2018 Oct;125(10):1547-1555
pubmed: 29776672
Retina. 2019 Feb;39(2):398-407
pubmed: 29190234
Clin Ophthalmol. 2016 Dec 20;11:39-46
pubmed: 28053499
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Trials. 2015 Sep 21;16:419
pubmed: 26390920
Prog Retin Eye Res. 2019 Nov;73:100770
pubmed: 31319157
Ophthalmology. 2008 Jan;115(1):169-73
pubmed: 18166410
Am J Ophthalmol. 2019 Sep;205:1-10
pubmed: 30951686
Eur J Ophthalmol. 2016 Aug 4;26(5):442-8
pubmed: 27135093
JAMA Ophthalmol. 2017 May 1;135(5):446-451
pubmed: 28334414
Acta Ophthalmol. 2018 Sep;96(6):e747-e749
pubmed: 29338129
Retina. 2020 Sep;40(9):1734-1741
pubmed: 31815877